| Literature DB >> 26199629 |
Weimin Guo1, Shuyun Liu1, Yun Zhu1, Changlong Yu1, Shibi Lu1, Mei Yuan1, Yue Gao1, Jingxiang Huang1, Zhiguo Yuan1, Jiang Peng1, Aiyuan Wang1, Yu Wang1, Jifeng Chen1, Li Zhang1, Xiang Sui1, Wenjing Xu1, Quanyi Guo1.
Abstract
The meniscus plays a crucial role in maintaining knee joint homoeostasis. Meniscal lesions are relatively common in the knee joint and are typically categorized into various types. However, it is difficult for inner avascular meniscal lesions to self-heal. Untreated meniscal lesions lead to meniscal extrusions in the long-term and gradually trigger the development of knee osteoarthritis (OA). The relationship between meniscal lesions and knee OA is complex. Partial meniscectomy, which is the primary method to treat a meniscal injury, only relieves short-term pain; however, it does not prevent the development of knee OA. Similarly, other current therapeutic strategies have intrinsic limitations in clinical practice. Tissue engineering technology will probably address this challenge by reconstructing a meniscus possessing an integrated configuration with competent biomechanical capacity. This review describes normal structure and biomechanical characteristics of the meniscus, discusses the relationship between meniscal lesions and knee OA, and summarizes the classifications and corresponding treatment strategies for meniscal lesions to understand meniscal regeneration from physiological and pathological perspectives. Last, we present current advances in meniscal scaffolds and provide a number of prospects that will potentially benefit the development of meniscal regeneration methods.Entities:
Year: 2015 PMID: 26199629 PMCID: PMC4496486 DOI: 10.1155/2015/517520
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Figure 1Top view of the anatomical meniscus (a): lateral meniscus is “O” shaped, whereas the medial meniscus has a “C” appearance. The meniscal functional unit (b), including the corresponding anterior and posterior ligaments and entheses. Entheses typically contain ligaments, uncalcified fibrocartilage, calcified fibrocartilage, and bone.
Figure 2The complex composition of the meniscal cellular and meniscal extracellular matrix (ECM) components. The outer region is the outer one-third of the meniscus; the inner region is the inner two-thirds of the meniscus; the superficial region is the surface of the meniscus.
Figure 3Schematic diagram of the meniscus force-bearing mechanism. Meniscal configuration adapts well to the corresponding shape of the femoral condyles and the tibial plateau in the knee joint. The axial load force (F) perpendicular to the meniscus surface and horizontal force (f ) are created by compressing the femur (F ). F rebounds due to the tibial upgrade force (F ), whereas the f leads to meniscal extrusion radially, which is countered by the pulling force from the anterior and posterior insertional ligaments. Consequently, tensile hoop stress is created along the circumferential directions during axial compression.
Figure 4The interaction between meniscal injury and knee osteoarthritis (OA). Knee mechanics become abnormal when a meniscus is injured, which leads to increasing stress across adjacent cartilage and subchondral bone. This stress triggers release of inflammatory cytokines, which further impair the meniscal extracellular matrix (ECM) and accelerate the vicious cycle of knee OA. OA of the knee joint also causes release of inflammatory cytokines, repeating the vicious cycle.
Figure 5Schematic diagram of the eight different types of meniscal lesions according to Casscells classification.
Summary of main studies concerning the bioabsorbable synthetic polymer scaffolds.
| Polymers type | Fabrication method | Cellular type |
| Stimulations | Time | Results | References |
|---|---|---|---|---|---|---|---|
| PGA bonded PLGA | Lyophilization | Allogeneic rabbit meniscal chondrocytes |
| None | 36 weeks | Proteoglycan types I and II collagen in neomenisci | Kang et al. (2006) [ |
|
| |||||||
| Pu | Solvent leaching | None |
| None | 24 weeks | Unorganized collagen deposition in isotropic scaffolds |
De Mulder et al. (2013) [ |
|
| |||||||
| PLDLA/PCL-T | Solvent casting and particulate leaching | Rabbit meniscus fibrochondrocytes |
| None | 24 weeks | Without apparent rejection, infection, or chronic inflammatory response | Esposito et al. (2013) [ |
|
| |||||||
| PEO loaded collagenase | Electrospinning | None |
| None | 4 weeks | Improved repair by promoting cell migration, proliferation, and matrix deposition | Qu et al. (2013) [ |
|
| |||||||
| PCL | Electrospinning | Juvenile bovine MSCs |
| Collagenase and ChABC | 120 days | Collagen dominated tensile response, GAG dominated compressive properties, and GAG removal result in significant stiffening in tension | Nerurkar et al. (2011) [ |
|
| |||||||
| PCL mixed PEO | Electrospinning with rotating mandrel | Juvenile meniscus fibrochondrocytes |
| Various porosity and preseeding | 8 weeks | Highly porous scaffolds integrate better with a native tissue and mature, preseeding improved |
Ionescu and Mauck (2013) [ |
|
| |||||||
| HYAFF/PCL | Lamination | Autologous chondrocytes |
| Transosseous | 4 months | Better implant appearance was in without fixation group; significant cartilaginous tissue formation and lower joint degeneration was in cell-seeded group | Kon et al. (2008) [ |
|
| |||||||
| HYAFF/PCL | Lamination | Autologous chondrocytes |
| None | 12 months | Avascular cartilaginous formation was more frequent in cell-seeded constructs; OA was less in cell-seeded group than in meniscectomy group | Kon et al. (2012) [ |
|
| |||||||
| Actifit | — | None |
| None | 12 months | Promoting tissue ingrowth into porous scaffolds | Galley et al. (2011) [ |
|
| |||||||
| Actifit | — | None | Clinical cases (54 patients) | None | 24 months | Significant improvements of pain and function scores; scaffold is safe and effective in treating lateral meniscus defects | Bouyarmane et al. (2014) [ |
|
| |||||||
| Actifit | — | None | Clinical cases | None | 24 months | Scaffold with chronic segmental medial meniscus deficiency is not only a safe procedure but leads to good clinical results |
Schüttler et al. (2014) [ |
|
| |||||||
| Actifit | — | None | Clinical cases | None | 24 months | No deleterious effects on patients | Baynat et al. (2014) [ |
PLDLA/PCL-T: poly (L-co-D,L-lactic acid)/poly (caprolactone-triol).
PEO: poly (ethylene oxide).
HYAFF/PCL: hyaluronan-derived polymers obtained by a coupling reaction (Fidia Advanced Biopolymers, Abano Terme, Italy).
Actifit: acellular meniscal scaffold mainly composed of PU (20%) and PCL (80%) (Orteq Sports Medicine, London, UK).
Summary of main studies concerning the absorbable scaffolds derived from biological components.
| Biological components | Source | Cellular type |
| Stimulations | Time | Results | References |
|---|---|---|---|---|---|---|---|
| Collagen sponge | Purified porcine skins | Human meniscal cells |
| TGF- | 14 days | Attached well and expanded with culture time | Gruber et al. (2008) [ |
|
| |||||||
| Collagen-GAG | Bovine tendon collagen type I and C6S | Human chondrocytes and meniscal cells |
| PDGF-BB and TGF- | 21 days | Increased contraction of collagen-GAG matrix induced by TGF- | Zaleskas et al. (2001) [ |
|
| |||||||
| Hyaluronan (HYAFF-11) | — | Bovine articular chondrocytes |
| Rotary cell culture system | 4 weeks | Outer stained for versican and type I collagen; inner positively stained for GAGs and types I and II collagen | Marsano et al. (2006) [ |
|
| |||||||
| Collagen II/I, III | Porcine collagen | Ovine meniscal cells |
| None | 28 days | Cells attached well to both biomaterials and produced GAGs and collagen type I | Chiari et al. (2008) [ |
|
| |||||||
| Hyaluronan (HYAFF-11) | — | Ovine meniscal cells |
| None | 28 days | Differences between the biomaterials were to cell distribution, morphology, and dynamics of GAGs synthesis | Chiari et al. (2008) [ |
|
| |||||||
| C6S coated PLGA surfaces | Shark C6S | Human meniscus fibrochondrocytes |
| Hypoxia | 14 days | Fibrochondrocytes redifferentiation were enhanced by hypoxia independent of hypoxia inducible factor (HIF) and potentially involve the transcriptional activation of Sox-9 | Tan et al. (2011) [ |
|
| |||||||
| Collagen type I (CMI) | Achilles tendon of bovine | Human BMSC |
| Biomechanical stimulation and perfusion | 14 days | Cell proliferation can be enhanced using continuous perfusion | Petri et al. (2012) [ |
|
| |||||||
| Collagen type I (CMI) | Achilles tendon of bovine | None | Clinical cases | None | 10 years | Significant pain relief and functional improvement | Monllau et al. (2011) [ |
|
| |||||||
| Collagen type I (CMI) | Achilles tendon of bovine | None | Clinical cases | None | 10 years | Pain, activity level, and radiological outcomes are significantly improved | Zaffagnini et al. (2011) [ |
|
| |||||||
| Multilayered silk scaffolds |
| Human fibroblasts (outside) chondrocytes (inside) |
| TGF- | 28 days | Maintenance of chondrocytic phenotype with higher levels of | Mandal et al. (2011) [ |
|
| |||||||
| Multilayered silk scaffolds |
| Human bMSC |
| TGF- | 28 days | Higher levels of collagens and GAGs | Mandal et al. (2011) [ |
|
| |||||||
| Bacterial cellulose |
| 3T6-swiss albino fibroblasts |
| Compression bioreactor | 28 days | Microchannels facilitated the alignment of cells and collagen fibers |
Martínez et al. (2012) [ |
Hyaluronan (HYAFF-11): (Fidia Advanced Biopolymers, Abano Terme, Italy).
Collagen II/I, III: Geistlich Biomaterials (Wolhusen, Switzerland). Two layers; the less porous layer consisted of collagen type I and type III; the porous layer consisted of collagen type II.
Collagen type I (CMI): distributed by Ivy Sports Medicine (ISM) (formerly known as ReGen Biologics).